ASH 2015 | Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of lenalidomide/dexamethasone with/without elotuzumab in patients with relapsed/refractory multiple myeloma (MM). In previous trials, the combination was very active with over 80% response rate. This Phase III trial led to the approval of the elotuzumab in the USA, and demonstrated a 30% improvement in duration of remission, a higher overall response, and the combination also showed activity in high-risk MM patients, in particular the ones with 17p and (4;14) translocation. These results were presented at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
Get great new content delivered to your inboxSign up